What is it about?
The promising clinical efficacy of the purely PI3K-delta selective inhibitor idelalisib prompted us to assess novel inhibitors of similar chemical structure, which additionally target PI3K-alpha (copanlisib) or gamma (duvelisib).
Featured Image
Why is it important?
Copanlisib inhibited the survival of CLL cells, at least ten-fold more efficiently than idelalisib and duvelisib. Survival inhibition by copanlisib was cell-type selective, accompanied by strong reduction of chemotaxis, efficacious in the presence of stroma cell support and enhanced by monoclonal antibodies, while antibody-dependent cell-mediated cytotoxicity for a CLL cell line was not disturbed.
Read the Original
This page is a summary of: Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells, International Journal of Cancer, May 2015, Wiley,
DOI: 10.1002/ijc.29579.
You can read the full text:
Resources
Contributors
The following have contributed to this page
